| Literature DB >> 32291490 |
Gwendal Gränicher1, Juliana Coronel2, Felix Trampler3, Ingo Jordan4, Yvonne Genzel5, Udo Reichl2,6.
Abstract
Process intensification and integration is crucial regarding an ever increasing pressure on manufacturing costs and capacities in biologics manufacturing. For virus production in perfusion mode, membrane-based alternating tangential flow filtration (ATF) and acoustic settler are the commonly described cell retention technologies. While acoustic settlers allow for continuous influenza virus harvesting, the use of commercially available membranes for ATF systems typically results in the accumulation of virus particles in the bioreactor vessel. Accordingly, with one single harvest at the end of a cultivation, this increases the risk of lowering the product quality. To assess which cell retention device would be most suitable for influenza A virus production, we compared various key performance figures using AGE1.CR.pIX cells at concentrations between 25 and 50 × 106 cells/mL at similar infection conditions using either an ATF system or an acoustic settler. Production yields, process-related impurities, and aggregation of viruses and other large molecules were evaluated. Taking into account the total number of virions from both the bioreactor and the harvest vessel, a 1.5-3.0-fold higher volumetric virus yield was obtained for the acoustic settler. In addition, fewer large-sized aggregates (virus particles and other molecules) were observed in the harvest taken directly from the bioreactor. In contrast, similar levels of process-related impurities (host cell dsDNA, total protein) were obtained in the harvest for both retention systems. Overall, a clear advantage was observed for continuous virus harvesting after the acoustic settler operation mode was optimized. This development may also allow direct integration of subsequent downstream processing steps. KEY POINTS: • High suspension cell density, immortalized avian cell line, influenza vaccine.Entities:
Keywords: Cell culture–based; Influenza; Perfusion; Virus
Mesh:
Year: 2020 PMID: 32291490 PMCID: PMC7228903 DOI: 10.1007/s00253-020-10596-x
Source DB: PubMed Journal: Appl Microbiol Biotechnol ISSN: 0175-7598 Impact factor: 4.813
Fig. 1Perfusion cell culture setups with AGE1.CR.pIX cells during the influenza virus production phase. The cells were retained in the bioreactor using an alternating tangential flow filtration (A), or an acoustic settler with either a pump-based (B) or a valve-based recirculation strategy (C). The acoustic settler allowed continuous virus harvesting, which was not feasible here with the ATF system due to membrane clogging. Fresh medium was added continuously (green arrow) to feed the cells, while cell-free medium was removed (red arrow) to keep a constant bioreactor working volume
Process conditions, cell retention efficiency, and product yields for influenza A/PR/8/34 virus using AGE1.CR.pIX cells in perfusion mode coupled with either an acoustic settler (different operation modes) or an ATF system
| ATF | Acoustic settler | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| s 1 | Run 2a | Run 3 | Run 4 | Run 5 | Run 6 | Run 7 | Run 8 | Run 9 | Run 10 | |
| Bioreactor working volume (mL)b | 750c | 800 | 600 | 670 | 600 | 600 | 680 | 600 | 1380 | 670 |
| Recirculation strategy | - | - | Valve | Valve | Pump | Pump | Pump | Pump | Pump | Pump |
| Recirculation rate ([day−1)b | - | - | 4.1 | 3.4 | 3.7 | 5.0 | 7.9 | 5.0 | 3.8 | 4.9 |
| Max. back-flushing flow rate (mL/min) | - | - | 53.4 | 11.2 | 2.8 | 3.2 | 4.8 | 3.0 | 5.5 | 3.6 |
| Shear rate γ (s−1) | 2451 | 3395 | 336 | 70 | 17 | 20 | 30 | 19 | 34 | 23 |
| Net perfusion rate (day−1)b | 2.1 | - | 1.8 | 2.0 | 2.1 | 1.9 | 1.9 | 1.5 | 1.5 | 2.1 |
| - | - | 14 | 11 | 9 | 13 | 11 | 16 | 7 | 10 | |
| T range inlet line (°C)d | - | - | 31–37 | 32–38 | 31–34 | 32–35 | 31–35 | 33–36 | 30–33 | 31–35 e |
| T range outlet line (°C)d | - | - | 38–40 | 37–40 | 39–40 | 40–41 | 39–40 | 42–43 | 37–38 | 39–40 e |
| VCC at TOI (106 cells/mL) | 25.4 | 23.8 | 24.8 | 24.7 | 26.7 | 25.0 | 25.1 | 24.8 | 26.8 | 49.3 |
| Max. VCC p.i. (106 cells/mL) | 37.7 | 23.8 | 35.1 | 30.3 | 36.7 | 34.6 | 32.5 | 27.2 | 32.6 | 69.4 |
| Viable cell retention efficiency p.i. (%) | 100.0 | 100.0 | 98.9 | 98.7 | 96.7 | 91.6 | 86.6 | 91.6 | 86.4 | 94.4 |
| Dead cell retention efficiency p.i. (%) | 100.0 | 100.0 | 97.7 | 98.6 | 96.1 | 83.2 | 88.8 | 92.5 | 81.0 | 84.3 |
| Total number of produced virions (1013 virions)f | 1.90 | 0.48 | 1.36 | 0.93 | 2.48* | 2.85* | 1.37 | 1.90 | 3.33* | 6.93* |
| CSVY (virions/cell) | 723 | 340 | 643 | 520 | 1124* | 1371* | 704 | 1163 | 1701* | 1665* |
| 5.49 | 1.81 | 5.38 | 2.79 | 7.11 | 9.28* | 3.59 | 6.98h | 16.49h* | 13.90* | |
ATF, alternating tangential flow; Valve, valve-based recirculation mode; Pump, pump-based recirculation mode; RV, reactor volume; Max., maximum; τ, mean residence time; T, temperature; VCC, viable cell concentration; TOI, time of infection; p.i., post-infection; CSVY, cell-specific virus yield; P, volumetric virus productivity
*Significant higher value compared to control run 1
aFrom previous study (Vazquez-Ramirez et al. 2019)
bConstant for the virus production phase
cThe bioreactor was sampled 1 time with a 50-mL sampling volume p.i. The working volume was then corrected to avoid a dilution with fresh medium, and started with 800 to 750 mL working volume
dDetermined in a separate experiment as described in the “Perfusion cell culture” section
eDetermined from run 7 conditions (similar perfusion rate)
fTotal number of produced virions, normalized to a bioreactor working volume of 600 mL
gProcess time (from calculated Pv) is from a starting VCC of 1.2 × 106 cells/mL until time point of maximum HA titer reached
hVolumetric virus productivity calculated with a perfusion rate (1.5 day−1) lower than for the control run 1 (2.1 day−1) resulted in an over estimation of the Pv value
Fig. 2Growth of AGE1.CR.pIX cells cultivated in perfusion mode using different cell retention technologies and recirculation strategies. a Viable cell concentration (filled symbols) and cell viability (empty symbols) of one representative ATF run (run 1) (black circle), one representative run for the acoustic settler with valve-based recirculation (AcSE valve, run 4) (blue circle), and two representative runs for the acoustic settler with pump-based recirculation (AcSE pump, run 5 (red circle), and run 10 (red triangle)). b Cell population doubling time (td) calculated during the cell growth phase in perfusion mode (average between each sampling time point for each run ± standard deviation). The values correspond to run 1 for ATF (black), runs 3 and 4 for the acoustic settler with valve-based recirculation (blue), and runs 5 and 10 for the acoustic settler with pump-based recirculation (red). A CSPR of 0.06 nL/cell/day was applied for every perfusion run. Detailed operation conditions in Table 1
Fig. 3Influence of acoustic settler operation on viable cell concentration, viability, and lactate metabolism during the influenza A/PR/8/34 virus production phase with AGE1.CR.pIX cells. (a) Viable cell concentration, (b) cell viability, (c) lactate concentration in the bioreactor supernatant. (d) YLac/Glc yield. Run 1 (black circle): performed with the ATF system. Run 3 (blue circle) and run 4 (blue triangle): performed with the valve-based recirculation mode of the acoustic settler. Run 5 (red circle), run 6 (red triangle), and run 7 (red square): performed with the pump-based recirculation mode of the acoustic settler. Detailed operation conditions in Table 1
Fig. 4Host cell dsDNA and total protein impurity levels during influenza A/PR/8/34 virus production phase in AGE1.CR.pIX cells in perfusion mode using an ATF system (run 1, black) or an acoustic settler with pump-based recirculation (one representative optimized run, run 6, red). a Host cell dsDNA concentration (black circle) and total protein concentration (white circle). Dashed lines represent additional data from the ATF permeate line. b Accumulated dsDNA (black circle), accumulated total protein (white circle), and total number of produced virions over time (black triangle). c Host cell dsDNA per virion (striped columns) and total protein per virion (filled columns) at optimum harvest time point (average ± standard deviation of technical duplicates). For the ATF cultivation, the bioreactor content was harvested at 36 hpi. When using the acoustic settler, virions from the bioreactor were also collected at the optimum harvest time point which corresponded to 45 hpi. Detailed operation conditions in Table 1
Fig. 5Infectious titer of influenza A/PR/8/34 virus and size distributions during influenza A/PR/8/34 virus production phase in AGE1.CR.pIX cells in perfusion mode using either an ATF system or an acoustic settler with pump-based recirculation. (a) Total number of infectious influenza virus particles produced using an ATF system (run 1, black circle) or an acoustic settler (one representative optimized run, run 6, red circle). Size distributions of run 1 (ATF, b) and run 6 (acoustic settler, c). All samples were measured from the crude bioreactor supernatant. For graph b, black, blue, and red lines correspond to 24, 36, and 47 hpi, respectively. For graph c, black, blue, and red lines correspond to 25, 33, and 45 hpi, respectively. Detailed operation conditions in Table 1